In a study designed to assess epigenetic regulation of Nrf2, DIM increased Nfe2l2 mRNA in transgenic adenocarcinoma mouse prostate (TRAMP)-C1 prostate cancer cells by reversing the methylation status of the first five CpGs in the Nfe2l2 promoter. Here, NFE2L2 is linked to prostate cancer.